ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
about
Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunctionThe effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysisProtection against age-dependent renal injury in the F344xBrown Norway male rat is associated with maintained nitric oxide synthaseLow molecular weight fucoidan alleviates cardiac dysfunction in diabetic Goto-Kakizaki rats by reducing oxidative stress and cardiomyocyte apoptosis.Cultural Considerations: Pharmacological and Nonpharmacological Means for Improving Blood Pressure Control among Hispanic Patients.Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats.Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.Therapeutic inhibition of the renin angiotensin aldosterone system.Dedicated to evidence-based medicine and the evaluation of new therapeutic approaches in the fieldCombination of β Adrenergic Receptor Block and Renin-Angiotensin System Inhibition Diminished the Angiotensin II-Induced Vasoconstriction and Increased Bradykinin-Induced Vasodilation in Hypertension.
P2860
Q28569684-8CFF6E70-9F22-4B79-95EE-E54D09D2376FQ34122611-ABC81E3C-726A-4890-8316-0B07CB18354BQ34544342-B6AE5462-862C-4AF1-AC5D-538D956AF8ACQ34708259-73C87B6F-622E-4596-847F-8564A38F2157Q35417838-7195BB17-1B4B-481F-853E-2828EC5CB395Q35789287-9AF32004-2BDB-4B99-9CD1-B16F4CA18D95Q36296054-7BAF6585-0A37-498E-9A22-8974EE31AAA4Q37159292-976B14F3-917E-41E0-BDA7-8985D7A20614Q37489951-0332C345-845B-4871-9327-74938FE41BF7Q42416662-AC7C8F06-7039-4932-A865-3B19448A80BCQ44636397-20DD4D60-2CCF-4624-BA53-9BB5A5177267
P2860
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
ACE-inhibitor, AT1-receptor-an ...... on of the results of ONTARGET.
@en
ACE-inhibitor, AT1-receptor-an ...... on of the results of ONTARGET.
@nl
type
label
ACE-inhibitor, AT1-receptor-an ...... on of the results of ONTARGET.
@en
ACE-inhibitor, AT1-receptor-an ...... on of the results of ONTARGET.
@nl
prefLabel
ACE-inhibitor, AT1-receptor-an ...... on of the results of ONTARGET.
@en
ACE-inhibitor, AT1-receptor-an ...... on of the results of ONTARGET.
@nl
P2860
P356
P1476
ACE-inhibitor, AT1-receptor-an ...... ion of the results of ONTARGET
@en
P2093
Christoph Schindler
P2860
P304
P356
10.1177/1753944708094309
P577
2008-08-01T00:00:00Z